After complete surgical resection of localized renal cell carcinoma, there is no existing standard post-operative therapy that is known to prevent or delay the occurrence of metastatic disease. Recent studies of sunitinib (Sutent) and sorafenib (Nexavar) in patients with metastatic renal cell carcinoma have demonstrated that both drugs are effective in prolonging disease control and survival. Based on these encouraging results, CORT is participating in the national study (ECOG 2805) for adjuvant treatment of resected, non-metastatic renal cell carcinoma. Patients who have complete resection of their renal tumors are eligible. Patients will be randomly assigned to either placebo therapy, treatment with Sutent, or treatment with Nexavar. Duration of treatment is approximately one year. Both drugs are orally administered.
The risks of treatment on this study are fatigue, anemia, nausea, vomiting, diarrhea, proteinuria (protein in the urine), delayed wound healing, bleeding, or thrombosis.
For more information on our research studies, visit www.CORTPA.com, or speak with a Study Coordinator at 972-566-5588.
Tags: adjuvant therapy, ECOG 2805, kidney cancer, Nexavar, post-operative therapy, preventive therapy, Renal Cancer, renal cell carcinoma, sorafenib, sunitinib, Sutent
